NCT01055483View on ClinicalTrials.gov

A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

panobinostat/LBH589B

Trial Locations (6)

30625

Novartis Investigative Site, Hanover

60590

Novartis Investigative Site, Frankfurt

75181

Novartis Investigative Site, Paris

75475

Novartis Investigative Site, Paris

89081

Novartis Investigative Site, Ulm

01307

Novartis Investigative Site, Dresden

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY